Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes

Abstract The major anti-hypertensive (AHT) drug classes have been associated with differential risks of psychiatric disorders. However, existing data are limited largely to depression, and confounding variables have not always been controlled for. We sought to fill the evidence gap, using TriNetX An...

Full description

Bibliographic Details
Main Authors: Lucy Colbourne, Sierra Luciano, Paul J. Harrison
Format: Article
Language:English
Published: Nature Publishing Group 2021-05-01
Series:Translational Psychiatry
Online Access:https://doi.org/10.1038/s41398-021-01444-1
id doaj-02214146ace54ce899978c35e7b900e0
record_format Article
spelling doaj-02214146ace54ce899978c35e7b900e02021-05-30T11:50:19ZengNature Publishing GroupTranslational Psychiatry2158-31882021-05-011111910.1038/s41398-021-01444-1Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classesLucy Colbourne0Sierra Luciano1Paul J. Harrison2Department of Psychiatry, University of Oxford, Warneford HospitalTriNetX Inc.Department of Psychiatry, University of Oxford, Warneford HospitalAbstract The major anti-hypertensive (AHT) drug classes have been associated with differential risks of psychiatric disorders. However, existing data are limited largely to depression, and confounding variables have not always been controlled for. We sought to fill the evidence gap, using TriNetX Analytics, an electronic health records network. Amongst 58.6 million patients aged 18–90 years, patients prescribed a calcium channel blocker (CCB) were compared with those taking a diuretic, angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or β-blocker. Cohorts were propensity score-matched for age, sex, race, and blood pressure. Over a 2-year exposure period, we measured the incidence and risk ratio of a first diagnosis (ICD-10 codes), or a recurrence, of psychotic, affective, and anxiety disorders, as well as substance use disorders and sleep disorders. Cohort sizes ranged from 33,734 to 322,814. CCBs were associated with a lower incidence of psychotic, affective, and anxiety disorders than β-blockers (risk ratios 0.69–0.99) and a higher incidence than ARBs (risk ratios 1.04–2.23) for both first and recurrent diagnoses. Comparisons of CCBs with ACEIs or diuretics showed smaller risk ratios that varied between disorders, and between first episode and recurrence. AHT classes were also associated with the incidence of substance use and sleep disorders. Results remained largely unchanged after more extensive cohort matching for additional potential confounders. In a secondary analysis, a comparison between ARBs and ACEIs showed lower rates of psychotic, affective, and substance use disorders with ARBs, but higher risks of anxiety and sleep disorders. In conclusion, AHT classes are differentially associated with the incidence of psychiatric disorders. ARBs show the most advantageous profile and β-blockers the least. The apparent beneficial effects of ARBs merit further study.https://doi.org/10.1038/s41398-021-01444-1
collection DOAJ
language English
format Article
sources DOAJ
author Lucy Colbourne
Sierra Luciano
Paul J. Harrison
spellingShingle Lucy Colbourne
Sierra Luciano
Paul J. Harrison
Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes
Translational Psychiatry
author_facet Lucy Colbourne
Sierra Luciano
Paul J. Harrison
author_sort Lucy Colbourne
title Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes
title_short Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes
title_full Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes
title_fullStr Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes
title_full_unstemmed Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes
title_sort onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes
publisher Nature Publishing Group
series Translational Psychiatry
issn 2158-3188
publishDate 2021-05-01
description Abstract The major anti-hypertensive (AHT) drug classes have been associated with differential risks of psychiatric disorders. However, existing data are limited largely to depression, and confounding variables have not always been controlled for. We sought to fill the evidence gap, using TriNetX Analytics, an electronic health records network. Amongst 58.6 million patients aged 18–90 years, patients prescribed a calcium channel blocker (CCB) were compared with those taking a diuretic, angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or β-blocker. Cohorts were propensity score-matched for age, sex, race, and blood pressure. Over a 2-year exposure period, we measured the incidence and risk ratio of a first diagnosis (ICD-10 codes), or a recurrence, of psychotic, affective, and anxiety disorders, as well as substance use disorders and sleep disorders. Cohort sizes ranged from 33,734 to 322,814. CCBs were associated with a lower incidence of psychotic, affective, and anxiety disorders than β-blockers (risk ratios 0.69–0.99) and a higher incidence than ARBs (risk ratios 1.04–2.23) for both first and recurrent diagnoses. Comparisons of CCBs with ACEIs or diuretics showed smaller risk ratios that varied between disorders, and between first episode and recurrence. AHT classes were also associated with the incidence of substance use and sleep disorders. Results remained largely unchanged after more extensive cohort matching for additional potential confounders. In a secondary analysis, a comparison between ARBs and ACEIs showed lower rates of psychotic, affective, and substance use disorders with ARBs, but higher risks of anxiety and sleep disorders. In conclusion, AHT classes are differentially associated with the incidence of psychiatric disorders. ARBs show the most advantageous profile and β-blockers the least. The apparent beneficial effects of ARBs merit further study.
url https://doi.org/10.1038/s41398-021-01444-1
work_keys_str_mv AT lucycolbourne onsetandrecurrenceofpsychiatricdisordersassociatedwithantihypertensivedrugclasses
AT sierraluciano onsetandrecurrenceofpsychiatricdisordersassociatedwithantihypertensivedrugclasses
AT pauljharrison onsetandrecurrenceofpsychiatricdisordersassociatedwithantihypertensivedrugclasses
_version_ 1721419889968676864